
Cardiol Therapeutics Inc
TSX:CRDL

Fundamental Analysis


Revenue & Expenses Breakdown
Cardiol Therapeutics Inc
Balance Sheet Decomposition
Cardiol Therapeutics Inc
Current Assets | 25.3m |
Cash & Short-Term Investments | 23.3m |
Receivables | 346.7k |
Other Current Assets | 1.6m |
Non-Current Assets | 182.5k |
PP&E | 182.6k |
Other Non-Current Assets | -100 |
Free Cash Flow Analysis
Cardiol Therapeutics Inc
CAD | |
Free Cash Flow | CAD |
Earnings Waterfall
Cardiol Therapeutics Inc
Revenue
|
0
CAD
|
Operating Expenses
|
-40.3m
CAD
|
Operating Income
|
-40.3m
CAD
|
Other Expenses
|
4.5m
CAD
|
Net Income
|
-35.8m
CAD
|
CRDL Profitability Score
Profitability Due Diligence
Cardiol Therapeutics Inc's profitability score is 35/100. The higher the profitability score, the more profitable the company is.

Score
Cardiol Therapeutics Inc's profitability score is 35/100. The higher the profitability score, the more profitable the company is.
CRDL Solvency Score
Solvency Due Diligence
Cardiol Therapeutics Inc's solvency score is 64/100. The higher the solvency score, the more solvent the company is.

Score
Cardiol Therapeutics Inc's solvency score is 64/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
CRDL Price Targets Summary
Cardiol Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for
CRDL
is 9.95 CAD
with a low forecast of 8.59 CAD and a high forecast of 11.55 CAD.
Dividends
Current shareholder yield for CRDL is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?